Rhone-Poulenc Rorer To Boost EPS Over 10% By 2000

22 September 1996

Franco-American pharmaceutical company Rhone-Poulenc Rorer is hoping to increase its earnings per share by over 10% by the year 2000, it was revealed in Paris, France, this week, where the company staged an R&D meeting (see also pages 19-20).

Michel de Rosen, chairman of the firm, said: "we are not preparing for a big deal for 1996 but we are concentrating on the essence of our resources in the development of new products. Our philosophy is to grow, not to hunt."

Mr de Rosen would not be drawn on whether there is any truth in rumors of Rhone-Poulenc, R-PR's parent company, wanting to merge the unit with Elf Aquitaine's Sanofi or L'Oreal's Synthelabo. He said the firm's other priority is to build geographically, particularly in the USA, Japan and Southeast Asia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.